FDA — authorised 19 August 2005
- Application: NDA021862
- Marketing authorisation holder: HARROW EYE
- Local brand name: NEVANAC
- Indication: SUSPENSION/DROPS — OPHTHALMIC
- Status: approved
FDA authorised Topical Gutt Nepafenac 0.1% on 19 August 2005
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 19 August 2005; FDA has authorised it.
HARROW EYE holds the US marketing authorisation.